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Standardised parenteral nutrition formulations are routinely used in the neonatal intensive care units in Australia
and New Zealand. In 2010, a multidisciplinary group was formed to achieve a consensus on the formulations
acceptable to majority of the neonatal intensive care units. Literature review was undertaken for each nutrient and
recommendations were developed in a series of meetings held between November 2010 and April 2011. Three
standard and 2 optional amino acid/dextrose formulations and one lipid emulsion were agreed by majority
participants in the consensus. This has a potential to standardise neonatal parenteral nutrition guidelines, reduce
costs and prescription errors.
Keywords: Parenteral nutrition, Preterm, Neonates, StandardisationBackground
Parenteral Nutrition (PN) is routinely used in the neonatal
intensive care units (NICUs) in Australia and New Zealand
(ANZ). The majority use standardised PN formulations.
An email survey found there were 61 different neonatal
standardised PN formulations compounded and supplied
by one pharmaceutical company in October 2009 [1]. This
number does not include formulations prepared in-house
in some NICUs. In New South Wales (NSW) alone,
there were 32 different amino acid/dextrose (AA/Dextrose)
formulations.
In November 2010, representatives from various NICUs
in the region joined together to form a Neonatal PN
Consensus Group. The main objective was to achieve
consensus in developing standardised PN formulations
agreeable to the majority of the NICUs and to deliver
the recommended parenteral nutrient intakes to the
majority of the neonatal population in Perinatal NICUs.
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as to avoid errors by rotating frontline staff and are cost
effective.Consensus process
The group consisted of neonatologists, nursing staff and
pharmacists with an input from other experts including a
nutritionist and a paediatric gastroenterologist as needed.
This group initially consisted of 10 NICUs from the region
of New South Wales (NSW) and the Australian Capital
Territory (ACT). A series of face-to-face meetings and
email correspondence were held between November 2010
and April 2011. A systematic literature search was under-
taken and detailed reports were developed for each com-
ponent of PN. Levels of evidence (LOE) and grades of
recommendation (GOR) were allocated according to Na-
tional Health and Medical Research Council (NHMRC)
criteria [2]. Where good published evidence was unavail-
able, recommendations were discussed and, if necessary,
voted upon. Members were given plenty of opportunity
and time for a thorough literature review, free and open
discussion and an exchange of good practice tips among
the units. Each member of the group presented the out-
comes of the meetings in their individual units and feed-
back of the comments and suggestions to the consensusl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Pharmaceuticals Australia were present in some of the
meetings and correspondence, but their contribution was
limited to advice on the feasibility, stability, compatibility
and other pharmaceutical related issues on the formula-
tions recommended by the consensus group. All the writ-
ings of the manuscript were in no way influenced by the
company. The initial consensus process was completed in
June 2011. Subsequently, other tertiary NICUs within
Australia, New Zealand, Malaysia, Singapore and India
joined the consensus group and contributed to the deve-
lopment of consensus formulations. By April 2013, the
consensus group consisted of 22 NICUs from Australasia.
Outcomes
The Consensus Group addressed the following issues.
Standardised PN versus individualized PN
Formulations
Several observational studies have reported that the use
of standardised PN solutions is feasible and appears to
offer advantages in some but not all clinical settings
[3-7]. Individual studies reported use of standardised PN
increased energy and amino acid intake [4-6], calcium
and phosphate intake [5,6], reduced early weight loss [4]
and reduced costs [6]. The single report of significantly
better growth, without added clinical or laboratory com-
plications, from use of a more aggressive nutritional ap-
proach including individual PN is limited by the 5 year
time difference between groups and overall changes in
nutritional strategies [7]. The consensus Group agreed
that standardised PN offers advantages over routine
individualised PN in terms of providing adequate nutri-
tion to the majority of neonates in the NICUs without
significant alteration in biochemical responses, with the
potential for reduced cost and prescription error (LOE
111–2, GOR C).
Fluid intake
Systematic review of five studies taken together indicates
that restricted water intake significantly increases post-
natal weight loss and significantly reduces the risks of
patent ductus arteriosus and necrotizing enterocolitis
[8]. With restricted water intake, trends were reported
toward increased risk of dehydration and reduced risks
of bronchopulmonary dysplasia, intracranial haemor-
rhage, and death, but these trends are not statistically
significant. The consensus agreement was new standar-
dised PN should be formulated to provide the Recom-
mended Daily Intakes (RDIs) of nutrients at a total
water intake of 150 ml/kg/day. This includes 135 ml/kg/
day of AA/Dextrose formulation and 15 ml/kg/day water
in the 20% lipid emulsion. There was general agreement
on starting parenteral fluid intake at 60 ml/kg/day withdaily increase by 20–30 ml/kg/day to an average ma-
ximum of 150 ml/kg/day. However, starting fluid intake
can be higher in some VLBW infants due to high water
loss in the first few days. In such cases, the PN solutions
can still be used to provide the necessary daily intakes of
nutrients with extra fluid provided as non-PN solutions
(LOE 1, GOR B).
Calorie intake
Recommended parenteral caloric intake varies from 89 to
120 kcal/kg/day in preterm neonates [9-11]. Minimal en-
ergy requirements are met with 50–60 kcal/kg/day, but
100–120 kcal/kg/day facilitate maximal protein accretion
[12]. A newborn infant receiving PN needs fewer calories
(90–100 kcal/kg/day) than a newborn fed enterally be-
cause there is no energy lost in the stools and there is less
thermogenesis [13]. Trials of early and/or higher energy
intake in preterm infants have reported commencing in-
fants on up to 60 kcal/kg/day PN increasing to up to
90–108 kcal/kg/day associated with positive nitrogen
balance, glucose and biochemical tolerance, and growth
[14-16]. The consensus group proposed standardised
starter PN solution at 60 ml/kg/day and lipid emulsion
at 1 g/kg/day provides approximately 68 kcal/kg/day,
and the standardised preterm PN solution at 135 ml/kg/day
and lipid emulsion at 3 g/kg/day provides approximately
100 kcal/kg/day (LOE II, GOR B).
Amino acids
Trials assessing the efficacy of early (day 1) introduction of
amino acids have reported higher blood urea nitrogen
levels [17,18] and increased nitrogen/protein accretion
[15,17-22] and variable effects on glucose tolerance
[15,18,23,24]. Early use of amino acid solutions may im-
prove glucose tolerance [15,18,23] but may not overcome
the effect of a high glucose infusion rate [24]. Limited
effects on infant growth have been reported from early
introduction of amino acid solutions but no improve-
ments in other neonatal outcomes or long term neuro-
development reported. A systematic review concluded
there is insufficient evidence to guide practice regarding
the early versus late administration of amino acids to in-
fants less than 37 weeks gestation [25]. The Consensus
Group universally agreed to commence parenteral AA
within the first 24 hours of birth (LOE I, GOR C).
Trials assessing the efficacy of higher versus lower
early amino acid administration also report higher blood
urea nitrogen levels [14,18,26], and increased nitrogen/
protein accretion [18,27]. Rates of early amino acid in-
take ranged from 0.5 g/kg/day to 3.5 g/kg/day. The ma-
jority of studies did not report any significant differences
in initial weight loss or subsequent growth [14,16,18,28].
A single study reported reduced weight loss but in-
creased use of insulin for glucose intolerance from early
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pared to 1 g/kg/day [16]. Data suggest biochemical toler-
ance and improved nitrogen/protein balance commencing
with 2–2.4 g/kg/day amino acid [16,18,26] with limited
data reporting the biochemical safety at 3.0-3.5 g/kg/day
[15,27]. No improvements in other neonatal outcomes or
long term neurodevelopment reported. The Consensus
Group agreed to commence parenteral AA at 2 g/kg/day
(LOE II, GOR C).
Trials assessing the efficacy of higher maximal rates of
amino acid administration have assessed the effects of
up to 3.5-4 g/kg/day [14,15,26]. Higher rates of maximal
amino acid administration were associated with higher
blood urea nitrogen levels [14,26] and increased nitro-
gen/protein accretion [15]. No significant difference in
growth has been reported although this may reflect en-
teral nutrition practices. Blanco et al. studied the effect
of a high parenteral amino acid intake 2 g/kg/d at birth
to a max 4 g/kg/d by day 3 in 30 infants born <1000 g
and reported biochemical intolerance resulting in dis-
continuation of intervention in 6 extremely premature
infants with peak blood urea nitrogen >21 mmol/L
(60 mg/dl) and plasma ammonia level >97 μmol/L [26].
The peak blood urea nitrogen levels were well above
normative data [29] although metabolic acidosis was not
observed and plasma ammonia levels up to 123 μmol/L
may be normal in extremely low birth weight infants
[30]. The Consensus Group agreed to incrementally in-
crease amino acid infusions to a maximum 4 g/kg/day
over 3–5 days (LOE II, GOR C).
Carbohydrates
ESPGHAN recommend the rate of glucose infusion
should not exceed the maximum rate of glucose oxida-
tion as excessive glucose intake may be responsible for
hyperglycaemia [31]. Maximal glucose oxidation has
been reported in preterm infants to be 8.3 mg/kg per
min (12 g/kg per day) [32,33], and in term infants
13 mg/kg per min (18 g/kg per day) [34,35]. Elevated
neonatal blood glucose concentration has been linked to
adverse outcomes including death [36,37], intraventricu-
lar haemorrhage [36], late onset bacterial infection [38],
fungal infection [39,40], retinopathy of prematurity
[41-43] and necrotizing enterocolitis [38]. Attempts to
maintain glucose intake using insulin have yielded vari-
able results [44,45]. For prevention of hyperglycaemia, a
systematic review found two small trials which com-
pared lower versus higher glucose infusion rates [45].
These trials provided some evidence that a lower glucose
infusion rate reduced mean blood glucose concentra-
tions and the risk of hyperglycaemia, but had insufficient
power to test for significant effects on death or major
morbidities [16,46]. The trials had glucose infusion rates
up to 8.4 mg/kg/min in the first 7 days in the highestinfusion group. In contrast, the multicentre trial of in-
sulin infusion reported that although insulin infusion
reduced mean glucose concentrations and reduced hyper-
glycaemia, it resulted in an increase in the risk of death
before 28 days and an increase in the proportion of neo-
nates with a hypoglycaemic episode [47]. Glucose infusion
rates were higher in the insulin group compared to the
standard care group (median 9.3 versus 7.6 mg/kg/min).
The review concluded the evidence does not support the
routine use of insulin infusions to prevent hyperglycaemia
in VLBW neonates. A second systematic review found
two trials that compared use of insulin infusion for
treatment of hyperglycaemia [44]. Collins 1991 reported
that infants treated with insulin infusion received sig-
nificantly higher glucose infusion rates than infants
treated with no glucose reduction (20.1 ± 2.5 versus
13.2 ± 3.2 mg/kg/min), and significant increases in non-
protein energy intake and short-term weight gain [48].
Meetze 1998 reported glucose infusion rate averaged ap-
proximately 10.0 mg/kg/min in the insulin infusion group
and approximately 7.6 mg/kg/min in the glucose reduc-
tion group, and significant increase in total energy intake
[49]. Neither reported a significant difference in neonatal
mortality or morbidity.
Proposed standard preterm and term PN formulations
contain 10% and 12% dextrose respectively, providing
13.5 (9.4 mg/kg/min) and 17 g/kg/day (11.8 mg/kg/min)
at 135 ml/kg/day respectively (LOE 1, GOR C).
Sodium, Potassium and Chloride
Higher early sodium intake may be associated with early
hypernatraemia and increased oxygen requirements to
28 days [50-53]. There is insufficient evidence to deter-
mine an effect on other neonatal outcomes and morta-
lity [50,51]. Subsequent higher sodium intake may
reduce the incidence of hyponatraemia [50-52,54]. The
consensus group agreed on minimal sodium intake
approximately 1 mmol/kg/d on day 1 using a starter PN
formulation, with an increase to a maximum 4.5 mmol/
kg/d in preterm and 3.5 mmol/kg/day in term infants
(LOE II, GOR C).
Hyperkalaemia is a common complication in the first
48 hours of life in very low birth weight and/or very pre-
term [55]. In a clinical trial, it was not affected by early
and high administration of protein [26]. After 3 days,
balance studies reported a potassium intake of 2–
3 mmol/L/day resulted in a net retention of 1–2 mmol/
day [56,57]. The consensus group agreed on minimal
potassium intake using starter PN formulation, with
an increase in standard formulations to a maximum
3.0 mmol/kg/d in preterm and 3.5 mmol/kg/day in term
infants (LOE III-2, GOR C).
Hyperchloraemia (>115 mmol/L) is a common prob-
lem in VLBW infants on PN and is associated with
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hyperchloraemia and acidosis is reduced by partly re-
placing chloride with acetate in parenteral nutrition [58].
Consensus was to adopt the trial recommendation of the
first 3 mmol/kg/day of anion to be provided as chloride,
next 6 mmol/kg/day of anion to be provided as acetate
and thereafter as chloride again. Supplementation of
acetate beyond this level was associated with hypercarbia
[58] (LOE II, GOR C).
Calcium, Phosphate and Magnesium
The range of recommended doses of Ca and P delivered
by PN in preterm infants is wide, varying from 1.3-
3 mmol Ca/kg/day and 1.0-2.3 mmol P/kg/day, with a
Ca:P ratio in the range of 1.3-1.7 [9,10]. Lower doses
may be inadequate for some infants, compromising
short and long-term bone formation. Trials have re-
ported higher intakes of calcium and phosphate increase
mineral retention, bone mineral content and bone
strength [60,61]. However, the threshold for calcium-
phosphate precipitation limits the delivery of appropriate
amounts of Ca and P by PN [62]. Substitution of inor-
ganic phosphate by organic phosphate improves physi-
cochemical compatibility which trial evidence reported
allowed for increased mineral intake and mineral reten-
tion [63]. However, there is no registered organic phos-
phate in Australia. The consensus formulations are not
to exceed 12 mmol/L of calcium and 10 mmol/L of inor-
ganic phosphorus due to concerns about physicochemi-
cal compatibility and precipitates (LOE II, GOR C).
Balance studies indicate that a magnesium intake
0.375 mmol/kg/day may result in elevated serum magne-
sium levels without clinical evidence of hypomagnes-
aemia, and for Mg intake a minimum of 0.2 mmol/kg/
day and 0.3 mmol/kg/day would be appropriate for
LBW infants [64,65] (LOE 111–3, GOR C).
Heparin
Systematic review of prophylactic use of heparin for per-
ipherally placed percutaneous central venous catheters
found a reduced risk of catheter occlusion with no sta-
tistically significant difference in the duration of catheter
patency, risk of thrombosis, catheter related sepsis or ex-
tension of intraventricular haemorrhage [66]. Heparin
was added at 0.5 to 1 IU/ml to parenteral nutrition solu-
tion with no adverse effect reported. The consensus for-
mulations contain heparin 0.5 IU/ml (LOE I, GOR C).
Consensus AA/dextrose formulations
Based on the above principles, the Consensus Group
agreed on 3 standard and 3 optional standardised AA/
Dextrose formulations (Table 1). Three Standard formu-
lations are as follows:(1) Starter PN – suitable for both term and preterm
neonates in the first 1–2 days. It contains 33 g/L
of amino acids (AA 3.3%) and 10% dextrose. It
provides 2 g/kg/day of amino acids at 60 ml/kg/day.
It contains minimum Na (15 mmol/L) and no
potassium. This formulation may be used up to
120 ml/kg/day for occasional infants on fluid
restriction and renal impairment. At 90 ml/kg/day
this solution provides 3 g/kg/day amino acids
beyond which the recommended protein intake is
exceeded for term infants [10]. At 120 ml/kg/day
the solution provides 4 g/kg/day of amino acids
beyond which the recommended preterm intake is
exceeded [10].
(2) Standard Preterm PN – This is suitable for stable
preterm infants after the first 24 hours. It provides
4 g/kg/day of amino acids and 12 g/kg/day of
glucose at 135 ml/kg/day.
(3) Standard Term PN – Suitable for stable term
neonates after the first 24 hours of life. It provides
3 g/kg/day of amino acid and 18 g/kg/day of glucose
at 135 ml/kg/day.
Two optional AA/Dextrose solutions have also been
agreed upon by majority units to provide the PN for
preterm infants with hyponatraemia and hyperglycaemia.
(1) High Sodium Preterm PN – similar to standard
preterm PN with higher Na content (60 mmol/L)
provides Na 8 mmol/kg/day at 135 ml/kg/day along
with increased chloride and acetate.
(2) 7.5% Dextrose Preterm PN – similar to standard
preterm TPN with the exception of 7.5% dextrose
providing 10 g/kg/day glucose at 135 ml/kg/day.
Lipids
Administration of lipid in premature infants requiring
PN provides essential fatty acids and increases caloric in-
take with a low volume [10]. Two systematic reviews
found that although no side effects were reported there
was no statistically significant benefit of introducing
lipids before two to five days of age, including no benefi-
cial effects on growth [67,68]. However, essential fatty
acid deficiency occurs rapidly and can be prevented with
introduction of as little as 0.5 to 1 g/kg/day of lipid infu-
sion [67]. The Consensus agreed timing of commence-
ment of parenteral lipid will be determined by individual
NICUs with day 1 administration as an option (LOE 1,
GOR C).
Several types of intravenous lipid emulsions (IVLE) are
available for neonatal use including 100% soybean oil
based IVLEs (e.g. Intralipid 20%, Ivelip 20%); mixed 80%
olive oil/20% soybean oil IVLE (e.g. Clinoleic 20%);
mixed 30% soybean oil/25% olive oil/30% medium-chain
Table 1 Consensus AA/dextrose formulations
Starter PN Standard preterm PN High sodium preterm PN 7.5% dextrose preterm PN Term PN
Conc/Litre
AA, g 33 30 30 30 23
Glucose, g 100 100 100 75 120
Na, mmol 15 33 60 33 25
K, mmol 0 22 22 22 20
Cl, mmol 12 16 36 22 26
Ca, mmol 12 12 12 12 12
Mg, mmol 1.5 1.5 1.5 1.5 1.5
Ph, mmol 10 10 10 10 10
Acetate, mmol 5 40 44 40 13.5
Zinc, μg 0 3260 3260 3260 1900
Selenium, μg 0 20 20 20 20
Iodine, μg 0 8 8 8 8
Heparin, units 500 500 500 500 500
Osmol, mosm/L 813 790 790 651 847
At 135 ml/kg/Day
Energy, Kcal/kg/day† 72 70 70 57 77
AA, g/kg/day 4.5 4 4 4 3
Glucose, g/kg/day 13.5 13.5 13.5 10 16.2
Na, mmol/kg/day 2 4.5 8.1 4.5 3.4
K, mmol/kg/day 0 3 3 3 2.7
Cl, mmol/kg/day 1.6 2.2 4.9 3 3.5
Acetate mmol/kg/day 0.7 5.4 6 5.4 1.8
Ca, mmol/kg/day 1.6 1.6 1.6 1.6 1.6
Ph, mmol/kg/day 1.4 1.4 1.4 1.4 1.4
Mg, mmol/kg/day 0.2 0.2 0.2 0.2 0.2
Zinc, μg/kg/day 0 440 440 440 256
Selenium, μg/kg/day 0 2.7 2.7 2.7 2.7
Iodine, μg/kg/day 0 1 1 1 1
†Energy rates are based on estimated 4 kcal per each gram of glucose and protein.
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100% fish oil based IVLE (e.g. Omegaven). The IVLEs
are largely well tolerated. No reproducible clinical bene-
fits have been reported for any specific IVLE in newborn
infants [69-80]. Although reduced peroxide formation
[81] and some biochemical difference in infants have
been reported [78], a reduced incidence of cholestasis
has not been reported using any specific preparation in
newborns to date. After consideration of costs, the con-
sensus group agreed to continue with the current prac-
tice of olive oil based emulsion in the majority of NICUs
(LOE II, GOR C).
The current Consensus emulsion contains 20% lipid
and 80% water (Clinoleic 20%). In view of benefits in
neonatal morbidities reported in a systematic review [8],
the group proposed to include lipids in the total fluidintake, which equates to 15 ml/kg/d of water when the
lipid intake reaches 3 g/kg/day (LOE I, GOR B). The
proposed lipid emulsion with the vitamins are available
in 2 volumes: 50 ml opaque syringes and 150 ml bags.
Each 50 ml contains the following: Clinoleic 20% -
36 ml, Vitalipid 10% - 11.2 ml and Soluvit reconstituted
in water for injection – 2.8 ml.
Vitamins
Water and fat soluble vitamins (Soluvit and Vitalipid
10%) are added to the lipid emulsion to increase the
vitamin stability [82]. Table 2 shows the amount of vita-
mins supplied to infants through the proposed lipid
emulsion when run at 3 g/kg/day. The doses of vitamin
K, pyridoxine and riboflavin are above recommended
parenteral doses, and ascorbate below [9,10]. Loss of
Table 2 Parenteral RDIs of vitamins and the comparison
to the consensus formulations
Element Parenteral RDIs† Lipid emulsion @
3 g/kg/day
Vit A, IU/kg/day 700-1500 920
Vit D, IU/kg/day 40-160 160
Vit E, IU/kg/day 2.8-3.5 2.8
Vit K, μg/kg/day 10 80
Ascorbate, mg/kg/day 15-25 10
Thiamine, μg/kg/day 200-500 310
Riboflavine, μg/kg/day 150-200 360
Pyridoxine, μg/kg/day 150-200 400
Nicotinamide, mg/kg/day 4-6.8 4
Pantothenate, mg/kg/day 1-2 1.5
Biotin, μg/kg/day 5-8 6
Folate, μg/kg/day 56 40
Vit B12, μg/kg/day 0.3 0.5
†RDIs adapted from AAP 2009 and ESPGHAN2005 recommendations.
Table 3 Parenteral RDIs of trace elements and the
comparison to the consensus formulations
Element Parenteral RDIs† PN solution@
135 ml/kg/day
Zinc, μg/kg/day 450–500 (preterm) 440 (preterm)
250 (term) 256 (term)
Selenium, μg/kg/day 2-3 2.7
Iodine, μg/kg/day 1 1
Chromium, μg/kg/day 0 0 (may ‘contaminate’)
Copper, μg/kg/day 20 0 initial
20*
Manganese μg/kg/day 1 0 initial
1*
Molybdenum μg/kg/day 1 0 initial
1*
†RDIs adapted from ESPGHAN2005 recommendations. *Consensus
recommendation to add if more than 2 to 4 weeks PN.
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light is substantially reduced by adding the preparation
to the lipid infusate, covering and use of amber/dark sy-
ringes and tubing [83-85] (LOE II, GOR B).
Optimal doses and conditions of infusion for vitamins
in infants and children have not been established [10].
The doses of many vitamins (eg Thiamine, Riboflavin,
Folate, Vitamin B12, Pyridoxine, and Vitamin C) are
largely determined by studies determining vitamin levels
during intravenous supply undertaken with commer-
cially available mixtures [10,86-88].
Vitamin A: Systematic review found that supplementa-
tion of very low birthweight infants with vitamin A is as-
sociated with reduction in death or oxygen use at one
month of age and oxygen use at 36 weeks’ postmenstrual
age, but this needs to be balanced against the lack of
other proven benefits and the acceptability of treatment
[89]. Current dosing recommendations for parenteral
vitamin A supplementation for premature infants are
based on clinical studies measuring vitamin levels during
supplementation [10] (LOE I GOR C).
Vitamin C: A single randomised trial reported no sig-
nificant benefits or harmful effects were associated with
treatment allocation to higher or lower ascorbic acid
supplementation throughout the first 28 days [90]. The
lower group received 10 mg parenterally provided in
Soluvit and Vitalipid (LOE II, GOR C).
Vitamin D: The consensus formulation delivers vita-
min D 160 IU/kg/day, above the minimal required vita-
min D intake reported to maintain 25(OH) vitamin D
levels [64] and consistent with studies reporting stable
vitamin D status in preterm infants on PN [91] (LOE
III-3, GOR C).Vitamin E: Systematic review found Vitamin E supple-
mentation in preterm infants reduced the risk of intra-
cranial hemorrhage but increased the risk of sepsis. It
concluded evidence does not support the routine use of
vitamin E supplementation by intravenous route at high
doses or aiming at serum tocopherol levels greater than
3.5 mg/dL, supporting the current recommendation for
parenteral intake of vitamin E [92] (LOE I, GOR B).
Vitamin K: Preterm infants who received intramuscu-
lar Vitamin K 1 mg at birth, followed by parenteral in-
take (60 μg/day for infants <1000 g and 130 μg/day for
infants 1000 to 3000 g) had much higher vitamin K
plasma concentrations at 2 and 6 weeks of age than pre-
viously reported in healthy, term, formula-fed infants
(4–6 ng/mL) [93]. The only formulation available in
Australia delivers in excess of current recommendation
[10] and is associated with high vitamin K plasma con-
centrations (LOE 111–3, GOR C).
Trace elements
Chromium, copper, iodine, manganese, molybdenum,
selenium and zinc are essential micronutrients involved
in many metabolic processes. Table 3 shows the paren-
teral RDIs of trace elements (EPSGHAN) [10] and the
comparison to the consensus group formulations. Nutri-
tional deficiency in low birth weight or preterm infants
on parenteral nutrition has been mostly reported for
zinc and copper [94]. The risk is substantially increased
in surgical infants with increased gastrointestinal losses.
There are no reports of clinical manganese deficiency in
newborns on PN [94]. Copper and manganese may need
to be withheld if the neonate develops PN-associated
liver disease. Copper has the potential for hepatotoxicity
and biliary excretion is important for manganese which
is potentially neurotoxic [94]. Low blood selenium
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potential risk factor for chronic neonatal lung disease and
retinopathy of prematurity [95]. Iodine deficiency and ex-
cess have been reported in preterm infants, with iodine ex-
cess associated with transient hypothyroidism [96-98].
There have been few reports of chromium deficiency in
humans [94]. PN solutions may be contaminated with
chromium, causing serum concentrations to be signifi-
cantly higher (10%-100%) than recommended [99]. There
is a concern excess chromium intake may be associated
with renal impairment in preterm infants [100].
Zinc: Zinc doses are derived from clinical trials repor-
ting zinc levels and zinc balance in preterm and term in-
fants [101-103]. Clinical benefits from different parenteral
intake have not been reported in trials. Parenteral zinc
is recommended at a dose of 450–500 μg/kg/day for
premature infants and 250 μg/kg/day for infants less
than 3 months [10]. Zinc is recommended to be added to
solutions of patients on short-term PN from commence-
ment [10,94] (LOE II. GOR C).
Copper: Copper doses are derived from clinical trials
reporting copper levels and copper balance in preterm
and term infants [101-103]. Clinical benefits from differ-
ent parenteral intake have not been reported in trials.
Parenteral copper intake is recommended at a dose of
20 μg/kg/day [10], and commenced 2 to 4 weeks after
PN commencement [94]. Copper should be carefully
monitored in patients with cholestatic liver disease
[10,94] (LOE II, GOR C).
Selenium: Systematic review found supplementing very
preterm infants with selenium is associated with a re-
duction in episodes of sepsis, but was not associated
with improved survival, a reduction in neonatal chronic
lung disease or retinopathy of prematurity. Doses of
3 μg/kg/d may prevent a decline in cord levels and doses
up to 7 μg may be required to achieve concentrations
above those in cords and close to concentrations found
in healthy breast fed infants [95]. Selenium supply of 2
to 3 μg/kg/day is currently recommended for paren-
terally fed LBW infants [10] (LOE I, GOR C).
Iodine: Observation data suggest preterm infants receiv-
ing PN containing a mean iodine intake of 3 μg/kg/day are
in negative iodine balance [97]. However, the relationship
to transient thyroid dysfunction in preterm infants is un-
clear. Enterally fed infants are recommended to receive
iodine 11–55 μg/kg/day [104], although a small trial re-
ported no evidence of an effect of higher enteral iodine in-
take on thyroid hormone levels in very preterm infants
[105]. Iodine intake needs to be appraised in the context
of iodine status and iodine exposures of pregnant women
and their infants. The recommended parenteral intake is
currently 1 μg/kg/day [10] (LOE III-3, GOR D).
Manganese: A randomised trial comparing PN intake
of 1 μmol/kg/day versus 0.0182 μmol/kg/day reportedno significant difference between peak manganese levels
between groups [106]. However, peak levels in both
groups were above normal ranges and there was no sig-
nificant difference between groups in incidence of chole-
stasis or morbidity and mortality. Subgroup analysis raised
the concern that infants on the higher dose for >14 days
had an increased rate of cholestasis. Supplementation
should be stopped in infants with cholestasis [94]. In
infants receiving long-term PN, a low dose supply of no
more than 1 μg/kg/day (0.0182 μmol/kg/day) is recom-
mended [10] (LOE II, GOR C).
Molybdenum: Deficiency has not been reported in
newborns. Observational data led to the speculation that
an intravenous intake of 1 μg/kg/day would be adequate
for the LBW infant [107]. Intravenous molybdenum sup-
ply of 1 μg/kg/day (0.01 μmol/kg/day) is recommended
for the LBW infant [10] (LOE III-3. GOR D).
There are 2 commercial trace element formulas avail-
able in Australia and neither of them has the right mix
of trace elements for neonatal use. AUSPEN Neonatal
Trace elements (Baxter Healthcare Pty Ltd) contains
more copper and manganese but less zinc. Peditrace
(Fresenius-Kabi Pty Ltd) contains fluorine. Consensus
was to add zinc, selenium and iodine as individual trace
elements to all AA/Dextrose formulations. Exception is
the starter formulation to which trace elements could
not be added due to physico-chemical compatibility con-
cerns. For those infants, who are on exclusive PN for
more than 2–4 weeks with minimal enteral intake, other
trace elements (copper, manganese and molybdenum)
can be added to the formulations.
Duration of infusion
Parenteral nutrition solution: In a randomised trial enrol-
ling 166 infants, there is no significant difference in bac-
terial or fungal colonisation of infusate or neonatal sepsis
in infants receiving 24 or 48 hour infusions of parenteral
nutrition solution [108]. A before-after intervention study
reported extending PN solution hang time from 24 to
48 hours did not alter central line associated blood stream
infection rate and was associated with a reduced PN-
related cost and perceived nursing workload [109].
Lipid infusion: In previously mentioned randomised
trial, fungal contamination may be increased in infants
receiving lipid infusion for 24 hours compared to
48 hours [108]. In another trial randomising PN set
changes (rather than infants), microbial contamination
of infusion sets was significantly more frequent with
72-hour than with 24-hour set changes in neonates
receiving lipid solutions [110].
Physico-chemical stability
Bouchoud and colleagues studied the long term physico-
chemical stability of the standardised AA/Dextrose and
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similar concentrations to the ones we proposed in our
consensus. Their AA/Dextrose solutions contain 3% AA,
10.8% glucose and heparin 0.5 IU/ml and the lipid
emulsion was lipofundin with vitamins added to it.
AA/Dextrose was supplied in multilayered plastic bag and
lipid emulsions were supplied in polypropelene syringes,
similar to our practice. They demonstrated an optimal
physical and chemical stability of AA/Dextrose solutions
even if they are stored for a few weeks at room
temperature. Similarly, lipid emulsions containing vitamins
showed negligible difference in physical stability, lipid
peroxide and vitamin levels when stored at room
temperature for a few weeks.
The consensus recommended a hang time of 48 hours
for PN solution and lipid (LOE II, GOR C).Discussion
To our knowledge, this is the first consensus on the
standardisation of parenteral nutrition across a majority
of units. The main consensus achievement was to de-
velop evidence based standardised formulations which
can be implemented with minimal need for individual-
isation in the newborn population, and to provide
framework for further development as new evidence be-
comes available. Success was facilitated by the majority
NICUs participating in the consensus group already
using standardised PN formulations. At the time of
writing up this manuscript, 20 NICUs from Australia,
New Zealand, Singapore and Malaysia are currently par-
ticipating in the consensus group. NICUs in the group
variably implemented some or all the formulations.
The consensus group negotiated a universal price for
the whole Australia and fixed for 3 years. A common PN
clinical protocol has been developed which is being
implemented across many NICUs.
There are some limitations and gaps in the formula-
tions and some unresolved issues in the initial consen-
sus. Starter AA/dextrose formulation contain 33 g/L of
AA, which provides 2 g/kg/d of AA at 60 ml/kg/d. How-
ever, there are some extreme preterm infants who may
be receiving other intravenous infusions which clinicians
include in the total fluid intake resulting in a reduced
calorie and AA intake. Pharmaceutical advice at the time
of the consensus was not to exceed 33 g/L of AA due to
stability and compatibility concerns. There was consen-
sus on the addition of zinc, selenium and iodine but we
were unable to reach any consensus on the routine
addition of other trace elements.
Currently, there is an observational study underway
testing the safety and efficacy of the new consensus for-
mulations. The findings of this study may help further
improve these formulations.Conclusion
In conclusion, consensus is achievable in standardising the
PN formulations in the neonatal intensive care units. This
has the potential to improve nutrient intakes, quality
control, cost effectiveness and reduce prescription errors.
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